Gut Microbiome: Everyone wins
Aeromonas bacteria living in the gut of zebrafish produce a specific molecule to pacify the immune system of their host.
- Université Claude Bernard Lyon-1, France
- Ecole Normale Supérieure de Lyon, France
Microbes can be found in almost every environment – including other organisms. Some cause disease, but many of them live with their hosts in a mutually beneficial relationship, a type of symbiosis called mutualism (McFall-Ngai et al., 2013). These microbial communities are in constant communication with the organisms hosting them, and gut bacteria in particular are known to influence the development, metabolism, immune system and behavior of their hosts (Fraune and Bosch, 2010; Kohl and Carey, 2016).
To peacefully cohabit with each other, the immune system of the host needs to control the number of bacteria without resorting to levels of inflammation that would harm either the bacteria or the host. As in many other areas of research, model organisms are widely used to dissect the molecular mechanisms that orchestrate such complex interactions. For example, the zebrafish – often used for studying development – is a powerful model that can be used to investigate such associations at the tissue, cell and molecular levels.
Most research to date has focused on how the host benefits from symbiosis, and the question of how the microbes benefit has been largely overlooked. Now, in eLife, Karen Guillemin and colleagues at the University of Oregon and the Canadian Institute for Advanced Research – including Annah Rolig as first author – report new details about the relationship between zebrafish larvae and one of their gut symbionts, Aeromonas veronii (Rolig et al., 2018).
Aeromonas are the only group of bacteria that are present throughout the zebrafish life cycle, and they play important roles in immune defense, gut cell growth and the development of the pancreas (Stephens et al., 2015; Burns and Guillemin, 2017). Rolig et al. used a specific strain of A. veronii (Hm21) to study the interactions between the bacteria and immune cells called neutrophils, which are the first immune cells to respond to inflammation and travel to the infected area (Brugman, 2016).
The fish were raised in sterile environments and were devoid of any microbes. Then, single bacteria were added and the interactions with the immune system were analyzed. This revealed that the bacteria produce a molecule that dampens the immune response of the neutrophils and so reduces inflammation.
The sequence of the molecule, which they named AimA (short for Aeromonas immune modulator A), did not resemble any known molecule, but its 3D crystal structure was similar to a molecule secreted by human neutrophils known as Lipocalin-2. Indeed, in experiments mimicking injuries to the zebrafish gut, the protective effect of AimA against inflammation was compromised when mouse Lipocalin-2 was added to the mix. This suggests that both molecules compete for the same receptors on the immune cells because they have similar structures.
Next, Rolig et al. investigated how AimA affected the ‘fitness’ of the Aeromonas and the zebrafish. The researchers created bacteria that lacked AimA and its close paralog AimB, and evaluated their ability to colonize larval zebrafish. Without AimA and AimB, the bacteria were unable to colonize the gut and the number of neutrophils increased, which in turn lead to more inflammation in the gut. However, when purified AimA was added, the mutant bacteria were able to accumulate in the gut and the number of neutrophils went back to normal.
This suggests that AimA mediates the interactions between zebrafish and the Aeromonas bacteria for the benefit of both partners, illustrating a prototypical example of mutualism. AimA is a colonization factor that intervenes early in the establishment of the bacteria in the gut, suppressing the immune response and inflammation in the gut to ensure the survival of the bacteria and the host. By doing so, it potentially allows bacteria to produce different molecules, which may benefit the host in other ways.
Symbiotic relationships have largely been described with a host-centric view, hence many molecular mechanisms may have been overlooked. Rolig et al. add AimA to the sparse list of known mutualistic factors, such as a specific polysaccharide that allows the bacterium Bacteroides fragilis to colonize the gut by activating tolerance in specific immune cells (Round et al., 2011). The anti-inflammatory potential of AimA and its atomic structure pave the way for researchers to test its potential as a therapeutic agent. The study of Rolig et al. highlights the importance of unbiased basic research in the host-microbe field using simple animal models.
References
-
The zebrafish as a model to study intestinal inflammationDevelopmental & Comparative Immunology 64:82–92.https://doi.org/10.1016/j.dci.2016.02.020
-
The scales of the zebrafish: host-microbiota interactions from proteins to populationsCurrent Opinion in Microbiology 38:137–141.https://doi.org/10.1016/j.mib.2017.05.011
-
A place for host-microbe symbiosis in the comparative physiologist's toolboxJournal of Experimental Biology 219:3496–3504.https://doi.org/10.1242/jeb.136325
Article and author information
Author details
Publication history
Copyright
© 2018, Matos et al.
This article is distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,866
- views
-
- 142
- downloads
-
- 1
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Gut Microbiome: Everyone wins
eLife 7:e42676.
https://doi.org/10.7554/eLife.42676
Further reading
-
- Immunology and Inflammation
Natural killer (NK) cells can control metastasis through cytotoxicity and IFN-γ production independently of T cells in experimental metastasis mouse models. The inverse correlation between NK activity and metastasis incidence supports a critical role for NK cells in human metastatic surveillance. However, autologous NK cell therapy has shown limited benefit in treating patients with metastatic solid tumors. Using a spontaneous metastasis mouse model of MHC-I+ breast cancer, we found that transfer of IL-15/IL-12-conditioned syngeneic NK cells after primary tumor resection promoted long-term survival of mice with low metastatic burden and induced a tumor-specific protective T cell response that is essential for the therapeutic effect. Furthermore, NK cell transfer augments activation of conventional dendritic cells (cDCs), Foxp3-CD4+ T cells and stem cell-like CD8+ T cells in metastatic lungs, to which IFN-γ of the transferred NK cells contributes significantly. These results imply direct interactions between transferred NK cells and endogenous cDCs to enhance T cell activation. We conducted an investigator-initiated clinical trial of autologous NK cell therapy in six patients with advanced cancer and observed that the NK cell therapy was safe and showed signs of effectiveness. These findings indicate that autologous NK cell therapy is effective in treating established low burden metastases of MHC-I+ tumor cells by activating the cDC-T cell axis at metastatic sites.
-
- Genetics and Genomics
- Immunology and Inflammation
PIK3R1 encodes three regulatory subunits of class IA phosphoinositide 3-kinase (PI3K), each associating with any of three catalytic subunits, namely p110α, p110β, or p110δ. Constitutional PIK3R1 mutations cause diseases with a genotype-phenotype relationship not yet fully explained: heterozygous loss-of-function mutations cause SHORT syndrome, featuring insulin resistance and short stature attributed to reduced p110α function, while heterozygous activating mutations cause immunodeficiency, attributed to p110δ activation and known as APDS2. Surprisingly, APDS2 patients do not show features of p110α hyperactivation, but do commonly have SHORT syndrome-like features, suggesting p110α hypofunction. We sought to investigate this. In dermal fibroblasts from an APDS2 patient, we found no increased PI3K signalling, with p110δ expression markedly reduced. In preadipocytes, the APDS2 variant was potently dominant negative, associating with Irs1 and Irs2 but failing to heterodimerise with p110α. This attenuation of p110α signalling by a p110δ-activating PIK3R1 variant potentially explains co-incidence of gain-of-function and loss-of-function PIK3R1 phenotypes.
